Downloadable Slides with Notes

Share

Program Content

Activities

  • Integrating Oral SERDs: HR+/HER2- BC
    Integrating Oral SERDs Into Treatment for Patients With HR-positive/HER2-negative Metastatic Breast Cancer and Current Rationale or Medical Need
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 13, 2024

    Expires: November 12, 2025

  • Sequencing Oral SERDs: HR+/HER2- BC
    Sequencing Novel SERDs in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 15, 2024

    Expires: November 14, 2025

  • Managing Oral SERD Related AEs in HR+/HER2- MBC
    Managing AEs With Oral SERDs for Patients With HR+/HER2- Metastatic Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 15, 2024

    Expires: November 14, 2025

Faculty

cover img faculity

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader
Breast Oncology Program
UT Health San Antonio
MD Anderson Cancer Center
San Antonio, Texas

cover img faculity

Erica L. Mayer, MD, MPH

Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Lilly

AstraZeneca

Lilly